Clinical Trials

Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced that it has entered a definitive agreement to acquire all rights to the investigational compound bermekimab from XBiotech Inc. Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb) in...

Eugen, a clinical development service provider based in Uruguay, will support Clinerion’s expansion by promoting hospitals in the country to join Patient Network Explorer (PNEx), adding to the platform true global representativeness. They will use PNEx to provide clients with...

UK-based pharmaceutical company ImmuPharma has signed a licensing and development agreement with US-based Avion Pharmaceuticals for Lupuzor, a peptide therapeutic and a first-in-class autophagy immunomodulator for auto-immune disease systemic lupus erythematosus (SLE or lupus). Under the agreement, the two firms...

The global pharmaceutical company and service partner Inceptua Group (previously Multipharma GmbH) and Bendalis GmbH – German manufacturer of generic oncology drugs and special therapeutic agents, announce the signing of an exclusive clinical trial supply agreement for oncology generics. Through...

ERYTECH Pharma a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that the full results from its Phase 2b trial evaluating eryaspase in metastatic pancreatic cancer are now published online in...

Anixa Biosciences, Inc., a biotechnology company, announced a collaboration with Urology Centers of Alabama (UCA) in the Cchek early prostate cancer detection study. UCA will provide patient samples in Anixa's ongoing study, including support of clinical validation of Anixa's...

Biogen Inc, a global biotechnology company, announced the enrollment of the last patient in the global phase 3 STAR clinical study, which is evaluating the investigational gene therapy timrepigene emparvovec (BIIB111/AAV2-REP1) for the treatment of choroideremia (CHM). CHM is...